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Summary 
To determine whether N-ras expression is required at specific stages of the process of in vitro 
normal human hematopoiesis, adherent- and T lymphocyte-depleted  mononuclear marrow cells 
(A-T-MNC) or highly purified progenitors (CD34 + cells) were cultured in semisolid medium, 
under conditions that favor the growth of specific progenitor cell types, after exposure to N-ras 
sense and antisense oligodeoxynucleotides. N-ras antisense, but not sense, oligodeoxynucleotide 
treatment  of A-T-MNC  and  CD34 +  cells  resulted  in  a  significantly  decreased  number of 
granulocyte/macrophage colony-forming units (CFU-GM) induced by interleukin 3 (I1:3) or 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and of macrophage colonies (CFU-M) 
induced by M-CSF,  but not of granulocytic colonies induced with G-CSF or I1:5.  However, 
the same treatment significantly inhibited colony formation induced by each of the above factors 
in combination with 11:3. Megakaryocytic colony (CFU-Meg) formation from A-T-MNC or 
CD34 + cells in the presence of Ib6  +  I1:3  +  erythropoietin (Epo) was also markedly decreased 
after antisense oligodeoxynucleotide treatment. Erythroid colonies derived from A-T-MNC in 
the presence ofEpo (CFU-E) were not inhibited upon antisense treatment, whereas those arising 
from A-T-MNC or CD34 + cells in the presence of I1:3  +  Epo (BFU-E) were markedly affected. 
These results are consistent with the hypothesis that distinct signal transduction pathways, involving 
N-ras or not, are activated by different growth factors in different hematopoietic progenitor cells. 
D 
uring the process of hematopoiesis, pluripotent hema- 
topoietic stem cells generate lineage-specific progenitors 
that proliferate extensively and acquire a distinct phenotype 
before terminal differentiation into circulating myeloid and 
erythroid cells (1). This process is regulated by the coordinate 
activity of several hematopoietic growth factors, which, upon 
interaction with  their  membrane receptors,  are  likely to 
transmit the proliferation and/or differentiation activating 
signals from the cell surface membrane to the nucleus by ac- 
tivation of numerous sigual-transduction  pathways (2-5). Be- 
cause some hematopoietic growth factors receptors have tyro- 
sine kinase activity, or are associated  with other tyrosine kimses 
(6-8), it seems likely that phosphorylation of tyrosine residues 
on target molecules is involved in this process. Oncogene prod- 
ucts with constitutively enhanced tyrosine kinase activity 
activate the p21 ras protein (9), a member of a family of GTP- 
binding proteins that appear to be involved in transduction 
of growth signals inside the cell (10), via increased amount 
of the active GTP-bound protein. 
The receptors for platelet-derived  growth factor and epi- 
dermal growth factor transduce signals to initiate DNA syn- 
thesis through activation of p21 ras (11, 12). Stimulation of 
T lymphocyte proliferation by PHA, and their activation via 
CD3 complex or CD2 antigen, causes activation of p21 ras 
(13, 14). Increased levels of activated p21 ras, observed after 
treatment of several cell lines with I1:2, II:3, and GM-CSF 
(15), suggest a role for p21 ras in the response of different 
cell types to growth factor stimulation. To determine whether 
N-ras is directly involved in the regulation of normal hema- 
topoiesis, we studied the effects of inhibiting N-ras expres- 
sion on normal hematopoietic proliferation. Our approach 
is based on the assumption that the generation of hemato- 
poietic colonies in vitro closely reflects the process occurring 
in vivo under the influence of a variety of hematopoietic 
growth factors (5) and on the demonstration that antisense 
oligodeoxynucleotides can inhibit specific gene function in 
hematopoietic cells (16-18). 
Our findings support the possibility that N-ras protoon- 
743  j. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/92/03/0743/08 $2.00 
Volume 175  March 1992  743-750 cogene is involved in the regulation of human hematopoiesis 
through a differential growth factor-dependent activation in 
distinct  progenitor cell subpopulations. 
Materials  and Methods 
Cells.  Marrows were obtained by aspiration from the iliac crest 
of  healthy  volunteers  after  informed  consent.  Light-density 
mononuclear cells, separated  on Histopaque-1077 (Sigma Chem- 
ical Co., St. Louis, MO) density gradient, were enriched for hema- 
topoietic progenitors after removing adherent ceils and T lympho- 
cytes (A-T-MNC) t as described (19). A-T-MNC were used as such 
or were further enriched for immature hematopoietic progenitor 
(CD34 §  cells using HPCA-1 mAb (Becton Dickinson & Co., San 
Jose, CA) and Dynabead M-450 magnetic polystyrene  beads coated 
with sheep anti-mouse IgG1 (Fc) (Dynal, Oslo, Norway) (20). The 
yield of CD34 §  cells from A-T-MNC  ranged between 0.3  and 
2.7%  of the starting MNC population. 
Oligodeoxynucleotides.  These were synthesized on a DNA syn- 
thesizer (model 380B; Applied Biosystems, Inc., Foster City, CA) 
by means of B-cyanoethyl-phosphorymidite  chemistry as described 
(18). The sequences of N-ras antisense and sense oligodeoxynucleo- 
tides used are 5'-CAG TTT GTA CTC AGT CAT -3' and 5'- ATG 
ACT GAG TAC AAA CTG -Y; respectively, which is complemen- 
tary (or corresponding) to 18 nucleotides of exon I beginning with 
the initiation codon. N-ras mRNA was detected by amplification 
of a segment of N-ras exon 1 using the reverse transcription poly- 
merase  chain reaction (RT-PCR)  technique with a 5' synthetic 
primer (5' ATC TCA TTT TAC TAG GGT GG 3') and a 3' syn- 
thetic primer (5' CTG GTG TGA AAT GAC TGA GT 3'). The 
amplification product was detected by hybridization to a synthetic 
oligomer included in the amplified  segment (5' GTG GTG GTT 
GGA GCA GGT GGT GTT ~  AAA AGC GCA CTG 3') en- 
compassing nucleotides 746-784 of the human N-ras eDNA (21). 
flz-microglobulin (fl2m) mRNA levels were also analyzed by RT- 
PCR.  The 5' primer corresponds to nudeotides 280-301 of the 
fl2m mRNA sequence;  the 3' primer corresponds to nucleotides 
510-531; a 50-base probe used to detect the amplification product 
corresponds to nucleotides 351-400 (22). 
Oligomer Treatment of the Cells.  10  s A-T-MNC or 10  ~ CD34" 
cells were seeded into 12  x  75-mm tubes (Falcon Labware, Ox- 
nard,  CA) in  0.4  ml of IMDM  supplemented with  2%  heat- 
inactivated human AB serum, recombinant human growth factors, 
Hepes buffer (Hazelton Biologics Inc.) and N-ras antisense or sense 
oligodeoxynucleotides.  Recombinant  human  growth  factors 
(Genetics Institute, Cambridge, MA) were Ib6 (125 U/ml), IL-3 
(50 U/ml), GM-CSF (12.5 ng/ml), M-CSF (50 U/ml), IL-5 (1:1,000 
crude conditioned medium from a CHO cell line constitutively 
expressing a human ID5 eDNA), G-CSF (1:10,000 crude condi- 
tioned medium from a CHO cell line constitutively expressing  a 
human G-CSF eDNA), and erythropoietin (Epo) (7.5 U/ml). Sense 
and antisense oligodeoxynucleotides were used at a concentration 
of 80/~g/ml during the first 18 h of incubation. Then a second 
dose (40 #g/ml) was added and cells were further incubated for 
6 h and plated without washing. Control groups were left untreated. 
Colony Assays.  Duplicate cultures were prepared in semisolid 
methylcellulose medium HCC 4230 (Terry Fox Labs, Vancouver, 
Abbreviations used in this paper: A-T-MNC, adherent- and T  lympho- 
cyte-depleted mononuclear marrow cells; Bzm, flz-microglobulin; Epo, 
erythropoietin; Meg, megakaryocytic;  KT, reverse transcription. 
Canada) or plasma clot (18). Concentrations of growth factors and 
human AB serum during culture were fivefold lower than those 
used during the oligodeoxynucleotide treatment. For mydoid colony 
stimulation (CFU-GM, CFU-M, CFU-Eo, or CFU-G), I1.-3, GM- 
CSF, M-CSF,  Ib5, and G-CSF were used, alone or in combina- 
tion. CFU-E were obtained in the presence of EPO alone. BFU-E 
were induced in the presence oflb3 and EPO. CFU-Meg were grown 
in the presence of IL-6, Ib3, and Epo. Cultures were carried out 
for 10-12  d, except for CFU-E,  cultured for 7-9 d. Plates  were 
then scanned with an inverted microscope and the number of colo- 
nies (/>50 cells) and clusters  (8-40 cells) were counted. Myeloid 
colonies were identified by visual inspection and erythroid colonies 
were counted after benzidine staining.  Immunofluorescence anal- 
ysis (23) with a glycoprotein IIb/IIIa-specific mAb (24) identified 
CFU- megakaryocyfic (Meg). Different oligodeoxynucleotide prepa- 
rations, several  bone marrow donors, and the same batches of human 
AB serum and HCC 4230 medium were used. Results of each ex- 
periment represent mean +  SD from 8-24 separate colony assays. 
Student's t test was used for statistical  analysis. 
Reverse Transc~ption  Polymerase Chain Reaction (RT-PCR).  To ana- 
lyze the effects of the N-ras oligodeoxynucleotides exposure on N-ras 
mRNA levels, 104 CD34 ~ cells were plated into 96-well plates in 
0.1 ml of IMDM supplemented with 2% human AB serum, IL-3 
and GM-CSF, Hepes buffer, and 80 #g/ml of N-ras antisense  or 
sense oligodeoxynucleotides. After 12 h, a second dose of oligomer 
(40 ~g/ml) was added and the incubation continued for additional 
12 h. Control cells were untreated. Cells were collected separately 
from each ~ental  group, centrifuged, washed, and total RNA 
was extracted as described (20). RNA from each group was divided 
into two portions. One sample was reverse transcribed using 400 U 
of Moloney murine leukemia virus reverse transcriptase (Bethesda 
Research Laboratories,  Gaithersburg, MD) and 0.1 #g of Y-end 
primer of N-ras exon 1 for 1 h at 37~  The second sample was 
reverse transcribed using the Bzm 3' primer.  For single colony RT- 
PCR analysis, individual colonies were plucked from methylcellu- 
lose and resuspended in 50/~1 of IMDM; cells were then centrifuged 
and lysed for 5 rain at 4~  in 7/~1 of 10 mM Tris-HC1, pH 8.0, 
10 mM NaC1, 3 mM MgCI: and 2% NP-40. The samples were 
then centrifuged at 12,000 rpm for 2 rain at 4~  and the superna- 
tants were used as a source of mRNA for reverse transcription reac- 
tion as above. Resulting cDNA fragments were amplified with 5 U 
of Taq polymerase (Perkin Elmer Cetus, Norwalk, CT) in the pres- 
ence of the 5' primer of either N-ras exon 1 or flzm, generating 
a 115-bp fragment of N-ras and a 252-bp fragment of fl2m eDNA 
during 50 cycles of PCR (25). Reaction products were subjected 
to electrophoresis in a 2% agarose gel, transferred to Zeta probe 
blotting membranes (Bio-Rad Laboratories,  Richmond, CA), and 
hybridized  overnight  at  55~  using  N-ras  or  flzm  synthetic 
oligomer end-labeled with 3r-[32p]ATP and polynucleotide kinase 
as described (26).  Filters  were washed twice with 2x  SSC con- 
taining 0.1% SDS at 49~  for 30 rain and exposed to x-ray films 
with intensifying screens. Densitometric measurements of the hy- 
bridization bands were performed using an Ultro Scan XL (Phar- 
macia,  LKB) apparatus. 
Results 
Effect of N-ras Antisense  Oligodeoxynucleotides  on Granulo- 
cyte/Macrophage  Colony Formation.  A-T-MNC were exposed 
to oligodeoxynucleotides (80/~g/ml at time 0; 40 #g/ml 18 h 
later) and plated (5  x  104 calls/plate) under optimal culture 
conditions for the growth of specific progenitor cell subsets. 
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growth stimulated with I1.3, GM-CSF, M-CSF, G-CSF, or 
Ib5 by 3.9,  1.5,  15.2, 0.4, and 2%, respectively,  compared 
with untreated controls. Instead, treatment with the N-ras 
antisense oligodeoxynucleotide resulted in 48.7,  36.0,  and 
67.5% inhibition of colony formation in the presence of II.-3, 
GM-CSF, or M-CSF, respectively, but did not affect colony 
formation in the presence of G-CSF or I1.5, compared with 
sense-treated  groups (Table 1). Colony size was only margi- 
nally affected by treatment with sense oligodeoxynucleotide, 
whereas the antisense treatment reduced the size of most colo- 
nies growing in the presence of I1.3, GM-CSF, or M-CSF, 
but not of those growing with I1.-5 or G-CSF  (data not 
shown). When A-T-MNC were cultured in the presence  of 
I1.3  +  GM-CSF, IL-3  +  M-CSF, I1-3  +  G-CSF, or II:3 
+  I1.5, sense oligodeoxynucleotide did not inhibit colony 
formation significantly (16.9, 7.4, 0, and 12.1%  inhibition, 
respectively) compared with controls, but treatment with N-ras 
antisense oligodeoxynucleotides  resulted in 38.6, 44.8, 35.9, 
and 38.4%  inhibition of colony formation compared with 
sense-treated  cultures (Table 1). 
To analyze the effect of N-ras antisense oligodeoxynudeo- 
tides on the growth of a more homogeneous, less mature 
population of hematopoietic progenitors, colony assays were 
performed  using  CD34 +  cells  isolated  from  A-T-MNC 
(Table 2). Treatment of the cells with sense oligodeoxynucleo- 
tides inhibited colony growth stimulated with II-3, GM-CSF, 
M-CSF, or G-CSF by only 0.6, 21.7, 16.7, and 10.7%, respec- 
tively,  compared with controls,  and colony size  was  not 
affected. Antisense oligodeoxynucleotide treatment, instead, 
efficiently inhibited the number of colonies induced with I1.3 
(73.6%), GM-CSF (53.3%), and M-CSF (61.5%), as com- 
pared with values obtained with sense oligomers (Table 2). 
As in the case of A-T-MNC, residual colony formation stimu- 
lated by G-CSF was not affected. I1.5 alone was not studied 
because  CD34 + cells do not form colonies in the presence 
of this cytokine (27).  When Ib3 was combined with GM- 
CSF,  M-CSF,  G-CSF,  or II.-5, sense oligodeoxynucleotide 
treatment reduced colony number only slightly (by 10.3, 12.3, 
13.3, and 1%, respectively) as compared with controls, whereas 
antisense treatment significantly  inhibited both the size (not 
shown) and the number of colonies (54.7,  79.1,  59.8,  and 
37.1%, respectively)  as compared with values obtained with 
the sense oligomer (Table 2). 
Effect of N-ras Antisense Oligodeoxynucleotides on Erythroid 
Colony Formation.  The influence of N-ras antisense oligode- 
oxynucleotides on BFU-E colony formation by A-T-MNC 
and CD34 + cells was evaluated  in the presence  of II,-3  + 
Epo (Tables 1 and 2). Sense oligodeoxynucleotide treatment 
did not significantly diminish colony number (10.3 and 11.2% 
inhibition, respectively) or size compared with controls. The 
antisense oligodeoxynucleotide inhibited colony number by 
20.4% (A-T-MNC) and 40.3% (CD34 +) compared with the 
sense oligomer, but only slightly reduced BFU-E colony size 
(not shown). Neither sense nor antisense oligodeoxynudeo- 
tides influenced the number or size of CFU-E colonies from 
A-T-MNC  in the presence  of Epo  only (Table  1).  Colony 
growth with Epo only was not studied with CD34 + cells 
because  CFU-E are not contained within this cell popula- 
tion (27). 
Effect  of N-ras  Antisense  Oligodeoxynucleotides  on  Mega- 
karyocytic Colony  Formation.  A-T-MNC  and CD34 +  cells 
were incubated in the presence  of I1:6  +  II.-3  +  Epo, and 
CFU-Meg colonies were identified by mAb immunofluores- 
cence  staining.  Sense  oligodeoxynucleotides did  not  sig- 
nificantly reduce colony number (8.3 and 14% inhibition com- 
Table  1.  Effect of N-ras Oligodeoxynucleotides on In  Vitro Colony Formation from A-T-MNC 
Number  of colonies/plate* 
Inducer  Control  Sense  Antisense  Percent inhibition~ 
IL-3  337.0  _+  24.1  325.7  _+  48.3  173.0  +  39.6  48.7 (p  =  0.035) 
GM-CSF  449.0  _+  58.0  465.0  _+  1.4  287.5  _+ 30.4  36.0 (p  =  0.016) 
M-CSF  75.5  _+  9.2  64.0  _+  4.2  24.5  _+  10.6  67.5 (p  =  0.039) 
G-CSF  119.5  +  34.6  120.5  _+  37.5  133.0  +  25.5  -10.4 (NS) 
IL-5  319.5  _+ 46.0  312.8  _+ 40.8  323.3  _+  22.1  -3.4 (NS) 
EPO  304.0  _+  138.7  284.9  _+  109.6  287.7  _+  135.4  -0.1 (NS) 
IL-3  +  GM-CSF  431.8  +_  91.5  358.6  _+  49.  213.5  _+  55.3  38.6 ~  <0.001) 
IL-3  +  M-CSF  356.5  _+  43.1  330.0  _+  14.1  182.0  _+  5.7  44.8 ~  =  0.005) 
IL-3  +  G-CSF  355.5  _+  17.7  355.0  _+  43.1  228.0  _+  50.9  35.9 (p  =  0.014) 
IL-3  +  IL-5  503.5  -+  76.0  423.0  _+  36  260.5  +_  39.6  38.4 (p <  0.001) 
IL-3  +  EPO  320.6  _+  61.3  287.5  _+  41.1  228.9  _+  39.6  20.4 ~  =  0.004) 
IL-6  +  IL-3  +  Epo  124.1  _+  22.1  113.8  _+  25.6  20.8  _+  11.1  81.7 ~  <  0.001) 
* Values are mean _+  SD from duplicate cultures from four to six separate experiments. 
Inhibition of colony  formation  by antisense oligodeoxynucleotides  in comparison  with sense-treated  groups (in parentheses, statistical  significance). 
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Number of colonies/plate" 
Inducer  Control  Sense  Antisense  Percent inhibitiont 
IL-3  128.8  +  27.1  128.0  +  7.6  34.0  +  5.8  73.6 ~  <  0.001) 
GM-CSF  116.2  _+ 36.7  91.0  _+  13.6  42.5  +  2.9  53.3 ~  <  0.001) 
M-CSF  56.2  +  14.3  46.8  _+ 9.0  18.2  +  4.3  61.5 (p  =  0.001) 
G-CSF  16.8  +  5.2  15.0  +  3.6  16.0  +  3.6  -0.1 (NS) 
IL-3  +  GM-CSF  135.2  +  17.3  121.3  +  17.6  54.9  +  14.2  54.7 (p <  0.001) 
IL-3  +  M-CSF  172.2  +_  14.2  151.0  +  24.8  31.5  _+ 4.7  79.1 (p <  0.001) 
IL-3  +  G-CSF  180.4  +  18.7  156.4  +  35.9  62.8  +  23.8  59.8 (p <  0.001) 
IL-3  +  IL-5  181.0  _+ 4.2  202.5  +  28.3  127.3  +  22.8  37.1 (p  =  0.006) 
IL-3  +  Epo  187.0  +  50.8  166.0  +  27.6  99.1  +  18.6  40.3 (p <  0.001) 
IL-6  +  IL-3  +  Epo  21.5  _+ 3.5  18.5  +  3.4  6.3  _+ 2.5  66.0 (p <  0.001) 
~ Values  are mean  _+  SD from duplicate cultures from 6-12 separate  experiments. 
* Inhibition of colony formation by antisense oligodeoxynucleotides in comparison with sense-treated groups (in parentheses,  statistical significance). 
pared  with  controls),  whereas  antisense  treatment  caused 
strong inhibition  of colony formation (81.7 and 66% com- 
pared with  sense)  (Tables  1 and 2).  Colony size was only 
slightly reduced in sense-treated cultures but markedly di- 
minished  after antisense treatment  (Fig.  1). 
Expression of N-ras mRNA  in CD34 + Bone Marrow Cells 
Exposed to N-ras Oligomers.  To determine whether the effects 
of N-ras antisense treatment on colony formation correlated 
with inhibition  of N-ras expression in hematopoietic cells, 
CD34 +  cells  were  exposed  to  N-ras  sense  or  antisense 
oligodeoxynucleotide and levels of N-ras mRNA were ana- 
lyzed by RT-PCR technique.  High levels of N-ras mRNA 
were detected in untreated (Fig. 2, lane c) as well as in sense- 
treated  CD34 +  cells  (Fig.  2,  lane  s).  Significantly  lower 
levels of N-ras mRNA were present in cells incubated with 
antisense oligodeoxynucleotide (Fig. 2, lane as). Densitomeric 
measurement of the N-ras cDNA hybridizing band in sense- 
versus-antisense-treated samples indicated that the signal from 
the  antisense-treated  cells was <5%  that  from  the  sense- 
treated cells.  I~wels of Bzm mRNA,  used as control,  were 
similar in all samples. Thus, treatment with N-ras antisense 
oligodeoxynucleotides causes a specific  downregnlation  of 
N-ras expression in CD34 § cells. 
Detection of  N-ras Transcripts in Individual Myeloid and Erythroid 
Colonies.  To determine whether the lack of inhibitory effect 
of N-ras antisense oligodeoxynudeotides on granulocyte and 
erythroid colony formation was due to the absence of N-ras 
expression in those specific colonies, single colonies obtained 
after stimulation with GM-CSF, G-CSF, IL-3 +  Epo, or Epo 
were analyzed for N-ras  mRNA  expression.  Each CFU-E 
colony consisted of 40-50 cells, whereas the number of ceils 
in the remaining colonies (BFU-E, CFU-GM, and CFU-G) 
was 200-250. Detection of N-ras mRNA by RT-PCR in each 
colony type (Fig. 3) indicates that the effect of N-ras antisense 
oligodeoxynucleotides on  the  different  colonies is  not  as- 
sociated with a stage-specific,  lineage-dependent pattern  of 
N-ras  expression. 
Discussion 
To assess the functional  significance of N-ras expression 
in normal hematopoietic progenitor cells, we exposed different 
progenitor cell subsets to N-ras antisense oligodeoxynucleo- 
tides and assayed colony formation in the presence of hema- 
topoietic  growth  factors  supporting  growth  of myeloid, 
erythroid,  or  megakaryocytic  progenitors.  The  antisense 
strategy has been successfully used for the functional analysis 
of numerous genes (28), including H-ras (29). The antisense 
oligodeoxynudeotide we used is specific for N-ras, and does 
not affect H-ras or K-ras expression, because of four and three 
nucleotide  mismatches,  respectively;  two  nudeotide  mis- 
matches are sufficient to abrogate the biological effect exerted 
by an 18-mer fully matched antisense oligodeoxynucleotide 
(30,  31).  Our results provide direct evidence that  N-ras  is 
required for growth of normal human hematopoietic calls. 
The N-ras antisense oligodeoxynucleotide inhibited myeloid 
colony formation derived from A-T-MNC as well as that de- 
rived from CD34 + cells in the presence of IL-3, GM-CSF, 
or M-CSF, but not G-CSF or Ib5, except when combined 
with Ib3. Colony size of most residual colonies formed after 
N-ras  antisense treatment  in the presence of Ib3,  or GM- 
CSF or M-CSF, was reduced compared with the sense-treated 
and control groups, although colony morphology was not 
altered. 
The number, but not the size, of early erythroid progen- 
itor colonies (BFU-E) growing from A-T-MNC or CD34 + 
cells in presence of Ib3  +  Epo was moderately reduced, but 
no influence of the antisense oligodeoxynucleotide on late 
746  Inhibition of Normal Hematopoiesis by N-ras Antisense Oligomers Figure 3.  Levels  of N-ras mR.NA in myeloid  and erythroid  colonies. 
Five individual  erythroid  (CFU-E and BFU-E) and myeloid  (CFU-GM 
and CFU-G) colonies  were isolated  after 5-d (BFU-E), 7-d (CFU-E and 
CFU-G), and 10-d (CFU-GM) culture  in methylcellulose.  Cytoplasmic 
RNA was extracted  and RT-PCR.  performed  for detection  of N-ras tran- 
scripts as described  in Materials  and Methods. flzrn  expression served as 
control, a, BFU-E; b, CFU-GM; c, CFU-G; d, CFU-E colonies. 
Figure 1.  Effect  of N-ras oligomers  on size of megakaryocytic  colony 
derived from A-T-MNC in the presence of II.-6 + Ib3  + Epo. (C) con- 
trol, (S) sense, (AS) antisense. 
Figure 2.  Expression  of N-ras 
and Bzm mRNA in CD34  + calls 
exposed  to  N-ras  oligodeox- 
ynucleotides. CD34  + cells (105/ 
ml) were left untreated (lane c), 
or exposed  to ",,80  ~g/ral  of  N-ras 
sense (lane  s) or antisense  (lane  as) 
oligodeoxynucleotides,  at time  0. 
After 12 h,  a second dose (40 
/~g/ml)  was added.  Cells  were  har- 
vested  12 h later, and mRNA  was 
isolated  and divided  into two aliquots  that were  separately  amplified  with 
N-ras and/3zm-specific  primers using RT-PCR. The resulting cDNAs 
were hybridized  to specific  3zp end-labeled  probes as described  in Materials 
and Methods. 
erythroid progenitor (CFU-E) colony formation was observed. 
The observation that colony formation was not inhibited in 
the presence of Epo, G-CSF, or 11.5 ex_cept when combined 
with Ib3 indicates that the lack of antisense inhibitory ac- 
tivity did not depend on either degradation of the oligodeox- 
ynucleotide or  inhibition  of its  cellular  uptake by  these 
cytokines. Together, these data suggest that N-ras is required 
for the growth of early but not of late myeloid and erythroid 
progenitor  cells.  The  observation that  the bone  marrow 
CD34 + subpopulation, which is enriched in pluripotent he- 
matopoietic stem cells, is more sensitive than the A-T-MNC 
population to  the inhibitory effect  of the N-ras  antisense 
oligodeoxynucleotide is consistent with this hypothesis. 
In contrast, during monocytopoiesis, N-ras appears to be 
required by early and late progenitors. Additional evidence 
to support the interpretation of these findings was obtained 
using different concentrations of M-CSF to exclude the pos- 
sibility that high concentrations of the cytokine would stimu- 
late CFU-GM colony formation. Based on morphological 
criteria, all of the colonies formed in the presence of M-CSF 
were of monocyte/macrophage origin (data not shown). 
N-ras is also needed for normal megakaryocytopoiesis, as 
indicated by the pronounced inhibition of CFU-Meg colony 
formation after antisense oligodeoxynucleotide treatment. 
N-ras requirements in normal human hematopoiesis ap- 
pear to be associated  with the activation of specific signal 
transduction pathways after the interaction of II-3, GM-CSF, 
747  Skorski  et al. and M-CSF, but not of G-CSF, I1:5, and Epo, with their 
respective receptors. Our data using GM-CSF and I1:3 sup- 
port and extend previous observations on in vitro established 
cell lines. An increase in GTP-bound p21 levels  in cells stimu- 
lated with PDGF (11), EGF (12), IL-2, I1:3, and GM-CSF, 
but not ID4 (15) or IGF-1 (32), has been reported and, based 
on that observation, it was suggested that p21 ras is required 
in the signal transduction pathway induced by these growth 
factors. The human GM-CSF  and I1:3 receptors exhibit  a 
striking homology in their primary structure (33); this is 
likely to explain their crossreactivity  with the respective  ligands 
and the apparent use of common molecular mechanisms of 
signal transduction (34). Accordingly, it might be difficult 
to determine whether the N-ras requirement is specifically 
associated with the GM-CSF or I1:3-dependent signal trans- 
duction pathway. 
We report the first evidence, to our knowledge, that N-ras 
is involved in the signal transduction pathway activated by 
M-CSF. Although there is no demonstration that M-CSF 
induces an increase in GTP-bound p21 levels directly, trans- 
formation of NIH 3T3 cells by the oncogenic form of the 
M-CSF receptor (v-fms) is inhibited by microinjection of the 
anti-Ras p21 antibody Y13-259 (35), supporting our conclu- 
sion that N-ras activation plays an important role also in the 
proliferative response induced by activation of the nononco- 
genic form of the M-CSF receptor. 
The possibility that the inhibition of BFU-E we observed 
upon I1:3  +  Epo stimulation does not depend directly on 
an effect of N-ras on erythroid colony formation stimulated 
by those cytokines cannot be excluded by our data.  It has 
been suggested that PDGF enhances, directly or indirectly, 
erythroid colony formation induced by Epo (36, 37); the pos- 
sibility that N-ras activation upon Epo stimulation occurs 
in response to PDGF, released by accessory cells or present 
in the serum used for culture, is unlikely because N-ras an- 
tisense oligodeoxynucleotide treatment does not affect  CFU-E 
colonies (Table 1). 
The receptors for hematopoietic growth factors either have 
intrinsic  tyrosine kinase activity  (M-CSF  receptor)  or are 
capable to activate these enzymes (I1:3, GM-CSF, G-CSF, 
and Epo receptors). Although the activation of the N-ras p21 
protein after growth factor stimulation might require phos- 
phorylation of the receptors and/or of target molecules, the 
mechanisms involved are not understood.  A mechanism by 
which p21 ras is maintained in the GTP-bound form involves 
inactivation  of GTPase activating protein (GAP); whether 
this is affected by phosphorylation or by other mechanisms 
is not yet clear (13, 15). It is possible, for instance, that the 
interaction  of Epo, or G-CSF or I1:5, with their receptors 
fails to generate the GTP-bound form of p21 ras or that the 
signal transduction pathway downstream of Ras is not acti- 
vated. Based on our observation that growth factor-induced 
colony formation has differential requirement for N-ras, there 
appear to be at least two distinct  pathways associated with 
proliferation of hematopoietic progenitor cells: one is associated 
with I1:3, GM-CSF, and M-CSF stimulation,  and the other 
with G-CSF, II:5, and Epo activity. Although our findings 
could be explained on the basis of a lineage-dependent mech- 
anism of N-ras activation, two observations are against this 
interpretation:  (a) residual colonies formed in the presence 
of GM-CSF after exposure to N-ras oligodeoxynucleotides 
were morphologically identified as granulocytic, macrophage, 
and mixed colonies (not shown);  and (b) comparable levels 
of N-ras  mRNA  were  detected  in  individual  erythroid 
(CFU-E), granulocytic  (CFU-G), and granulocyte/macro- 
phage (CFU-GM) colonies (Fig. 3). Further studies are needed 
to determine the basis for the involvement of N-ras in dis- 
tinct growth factor-dependent signal transduction pathways. 
The physiological role of protooncogenes in hematopoi- 
esis most likely involves the coordinate regulation of prolifer- 
ation and differentiation. Each step in the process of gener- 
ating terminally differentiated cells from muhipotent and 
unipotent progenitors  is probably under the control of sev- 
eral genes encoding products with distinct functions. We have 
previously demonstrated that c-rayb (18, 20) and c-abl (38) 
play a regulatory role in normal hematopoiesis, and we now 
report the involvement of N-ras in the process. Our results 
underscore the complexity of the regulatory mechanisms in- 
volved in hematopoiesis and provide a rational basis to ex- 
plain the pathological effects that may result from aberrant 
activation of protooncogenes.  It seems not unreasonable to 
hypothesize that the mutated form of N-ras, which is de- 
tected in many cases of acute myelogenous leukemia, bypasses 
certain regulatory steps associated with the developmental 
program of normal hematopoietic  cells. 
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